<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381326</url>
  </required_header>
  <id_info>
    <org_study_id>IRSTB030</org_study_id>
    <nct_id>NCT03381326</nct_id>
  </id_info>
  <brief_title>CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.</brief_title>
  <acronym>IRSTB030</acronym>
  <official_title>Biomarkers Study: Circulating Tumor Cells (CTC), Free DNA, Stem Cells and Epithelial-mesenchymal-transition (EMT) Related Antigens as Biomarkers of Activity of Cabazitaxel in Castration-resistant Prostate Cancer (CRPC): a Proof of Concept.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and
      EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment
      in castration-resistant prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Circulating Tumor Cells, free DNA, Stem Cells and EMT-related antigens as biomarkers of
      activity of cabazitaxel in castration-resistant prostate cancer

      Primary objectives: To evaluate the prognostic role of response of the copy number of
      androgen receptor (AR) and Phosphatase and tensin homolog (PTEN) and AR-V7 and other gene
      expression biomarkers in CTC and the investigators will compare these results with those
      obtained in plasma cell free DNA and RNA.

      Eligible patients must have histologically or cytologically confirmed prostate cancer or
      unequivocal increased PSA . Metastatic and/or inoperable disease and received prior therapy
      with docetaxel and candidate to cabazitaxel treatment.

      All patients receive cabazitaxel at standard schedule 25 mg/m2 q21. Blood sample will be
      collected for CTC evaluation at baseline, after the first cycle of therapy (optional), at
      first radiological evaluation (after 3 months), at disease progression (optional) or after
      9-12 months of treatment for patients who did not show disease progression (optional).
      Disease progression defined according to Prostate Cancer Working Group 2 (PCWG2) criteria. On
      blood samples from Castration-Resistant Prostate Cancer (CRPC) patients the investigators
      will investigate the presence of the previously presented CTC, DNA and RNA free markers.

      As an option, it will be possible to require a sample of the tumor collected during prostate
      surgery or during the biopsy.

      All patients will be treated and monitored according to the local clinical practice. No
      additional procedures/patient visits in comparison with the usual clinical practice are
      planned for the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>time between the start of cabazitaxel and the ﬁrst date of progression as measured by PCWG-2 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>The overall survival will be calculated from date of the start of cabazitaxel to death</description>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Castration-resistant Prostate Cancer</condition>
  <condition>Circulating Tumor Cells</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood and FFPE sample collection</intervention_name>
    <description>blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples and FFPE samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with castration-resistant prostate cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and the willingness to sign a written informed consent document

          2. Male aged &gt;18 years with metastatic castration-resistant disease with documented
             clinical (imaging) and/or biochemical progression (PSA increasing values) during or
             after a previous docetaxel-based chemotherapy

          3. Patients must have metastatic and/or inoperable disease

          4. Patients must have received prior therapy docetaxel based and must be candidate to
             cabazitaxel

          5. Life expectancy of greater than 3 months

          6. Eastern Cooperative Oncology Group (ECOG) performance status &lt;2

        Exclusion Criteria:

          1. Participants who are unable to provide informed consent

          2. Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ugo De Giorgi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ugo De Giorgi</last_name>
    <phone>+39 0543 739100</phone>
    <email>ugo.degiorgi@irst.emr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oriana Nanni</last_name>
    <phone>+39 0543 739100</phone>
    <email>oriana.nanni@irst.emr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedali Riuniti Umberto I</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano Burattini, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Matteo Santoni</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ugo De Giorgi, MD</last_name>
      <phone>+390543739100</phone>
      <email>Ugo.Degiorgi@irst.emr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile degli Infermi</name>
      <address>
        <city>Rimini</city>
        <state>RN</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Tassinari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Cannizzaro</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Luigi Banna</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Mosca</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico del Veneto (IOV) - Università di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto Basso, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Santini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore Don Calabria (Negrar)</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Nicodemo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>circulating tumor cells</keyword>
  <keyword>Castration-resistant Prostate Cancer</keyword>
  <keyword>cabazitaxel</keyword>
  <keyword>biomarker</keyword>
  <keyword>free DNA</keyword>
  <keyword>stem cells</keyword>
  <keyword>EMT related antigens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

